Associate Professor of Radiation Oncology, Dana-Farber Cancer Institute
Radiation Oncology
Dr. Roy B. Tishler, MD
|
|
Give Review
Doctor Roy B. Tishler, MD is an expert in the field of Radiation Oncology. He researched medicine at Johns Hopkins University School of Medicine. Johns Hopkins University School of Medicine is one of the top medical schools in the US. Johns Hopkins University School of Medicine is ranked 3/29 in Research/PrimaryCare. He has 2 awards "Meaningful Use Stage 1 Certification" and "Super Doctor". Roy B. Tishler is a published doctor. He has 78 papers published. The most current publication "Induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck: a phase I/II trial." He accepts all Medicare patients.
Publications
- Cost-Effectiveness Analysis of Chemoradiation Therapy Versus Transoral Robotic Surgery for Human Papillomavirus-Associated, Clinical N2 Oropharyngeal Cancer.
- Radiation Oncology-New Approaches in Squamous Cell Cancer of the Head and Neck.
- Thyroid malignancies in survivors of hodgkin lymphoma.
- Success of endoscopic pharyngoesophageal dilation after head and neck cancer treatment.
- Organ Preservation for Adenoid Cystic Carcinoma of the Larynx.
- Trastuzumab for the treatment of salivary duct carcinoma.
- Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and n...
- Acupuncture for dysphagia after chemoradiation in head and neck cancer: rationale and design of a randomized, sham-controlled trial.
- Treatment of oral cavity squamous cell carcinoma with adjuvant or definitive intensity-modulated radiation therapy.
- Swallowing Function following Postchemoradiotherapy Neck Dissection: Review of Findings and Analysis of Contributing Factors.
- Relationship Between Radiation Treatment Time and Overall Survival After Induction Chemotherapy for Locally Advanced Head-and-Neck Carcinoma: A Subset Analysis of TAX ...
- Efficacy and Toxicity of Chemoradiotherapy Using Intensity-Modulated Radiotherapy for Unknown Primary of Head and Neck.
- Salivary Gland Tumors Treated With Adjuvant Intensity-Modulated Radiotherapy With or Without Concurrent Chemotherapy.
- Efficacy and toxicity of reirradiation using intensity-modulated radiotherapy for recurrent or second primary head and neck cancer.
- Utilizing computed tomography as a road map for designing selective and superselective neck dissection after chemoradiotherapy.
- Combined antegrade and retrograde esophageal dilation for head and neck cancer-related complete esophageal stenosis.
- Head and neck carcinomas across the age spectrum: epidemiology, therapy, and late effects.
- Clinical practice guidance for radiotherapy planning after induction chemotherapy in locoregionally advanced head-and-neck cancer.
- Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally ad...
- Phase I study of C-TPF in patients with locally advanced squamous cell carcinoma of the head and neck.
- Effect of dental restorations and prostheses on radiotherapy dose distribution: a Monte Carlo study.
- Dose to larynx predicts for swallowing complications after intensity-modulated radiotherapy.
- Multidisciplinary approach to cancer treatment: focus on head and neck cancer.
- Clinical experience of the importance of daily portal imaging for head and neck IMRT treatments.
- Experimental evaluation of the impact of different head-and-neck intensity-modulated radiation therapy planning techniques on doses to the skin and shallow targets.
- Commentary: IMRT for head and neck cancer: many chapters left to write.
- Build-up and surface dose measurements on phantoms using micro-MOSFET in 6 and 10 MV x-ray beams and comparisons with Monte Carlo calculations.
- Retropharyngeal nodes in hypopharynx cancer on positron emission tomography.
- Dynamic IMRT treatments of sinus region tumors: comparison of Monte Carlo calculations with treatment planning system calculations and ion chamber measurements.
- Concurrent weekly docetaxel and concomitant boost radiation therapy in the treatment of locally advanced squamous cell cancer of the head and neck.
- Dysphagia after sequential chemoradiation therapy for advanced head and neck cancer.
- Examining the need for neck dissection in the era of chemoradiation therapy for advanced head and neck cancer.
- Chemoradiotherapy for adenoid cystic carcinoma: preliminary results of an organ sparing approach.
- Chemoradiation-induced cell loss in human submandibular glands.
- Induction chemotherapy in locally advanced squamous cell cancer of the head and neck: evolution of the sequential treatment approach.
- Endoscopic management of hypopharyngeal stenosis after organ sparing therapy for head and neck cancer.
- Positron emission tomography with 18F-fluorodeoxyglucose to predict pathologic response after induction chemotherapy and definitive chemoradiotherapy in head and neck ...
- Prospective phase II trial of PFL-induction chemotherapy followed by definitive local treatment for advanced squamous cell carcinoma of the head and neck: 10-year foll...
- Nonsurgical treatment of laryngeal cancer.
- Polymer-conjugated paclitaxel as a radiosensitizing agent--a big step forward for combined modality therapy?
- Docetaxel, cisplatin, 5-fluorouracil (TPF)-based induction chemotherapy for head and neck cancer and the case for sequential, combined-modality treatment.
- A Phase I/II trial of concurrent docetaxel and radiation after induction chemotherapy in patients with poor prognosis squamous cell carcinoma of the head and neck.
- Phase I/II trial of outpatient docetaxel, cisplatin, 5-fluorouracil, leucovorin (opTPFL) as induction for squamous cell carcinoma of the head and neck (SCCHN).
- Hypothyroidism incidence after multimodality treatment for stage III and IV squamous cell carcinomas of the head and neck.
- Multicenter phase Ib/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases.
- The role of induction chemotherapy in the curative treatment of squamous cell cancer of the head and neck.
- Phase II trial of docetaxel, cisplatin, fluorouracil, and leucovorin as induction for squamous cell carcinoma of the head and neck.
- An initial experience using concurrent paclitaxel and radiation in the treatment of head and neck malignancies.
- Induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck: a phase I/II trial.
- Induction chemotherapy with cisplatin, fluorouracil, and high-dose leucovorin for squamous cell carcinoma of the head and neck: long-term results.
- The interaction of taxol and vinblastine with radiation induction of p53 and p21 WAF1/CIP1.
- Microtubule-active drugs taxol, vinblastine, and nocodazole increase the levels of transcriptionally active p53.
- Increases in sequence specific DNA binding by p53 following treatment with chemotherapeutic and DNA damaging agents.
- Tolerance of cranial nerves of the cavernous sinus to radiosurgery.
- A study of the dynamic properties of the human red blood cell membrane using quasi-elastic light-scattering spectroscopy.
- Quasi-elastic light scattering studies of membrane motion in single red blood cells.
- Low dose rate irradiation and halogenated pyrimidine effects on human cervical carcinoma cells.
- Correlation of sensitizer enhancement ratio with bromodeoxyuridine concentration and exposure time in human cervical carcinoma cells treated with low dose rate irradia...
- Taxol sensitizes human astrocytoma cells to radiation.
- Taxol: a novel radiation sensitizer.
- Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas.
- Definitive radiotherapy with interstitial implant boost for squamous cell carcinoma of the tongue base.
- Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber C...
- Integrating novel agents into the curative treatment of head and neck cancer.
- Organ preservation and treatment toxicity with induction chemotherapy followed by radiation therapy or chemoradiation for advanced laryngeal cancer.
- Rate of pathologic complete responses to docetaxel, cisplatin, and fluorouracil induction chemotherapy in patients with squamous cell carcinoma of the head and neck.
- Evaluation of the precision of portal-image-guided head-and-neck localization: an intra- and interobserver study.
- Automatic online adaptive radiation therapy techniques for targets with significant shape change: a feasibility study.
- Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
- Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation.
- Options for combining altered fractionation with IMRT.
- Patient-reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy: demonstration of increased fre...
- Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of t...
- Cost-effectiveness of CT and PET-CT for determining the need for adjuvant neck dissection in locally advanced head and neck cancer.
- Experimental evaluation of the accuracy of skin dose calculation for a commercial treatment planning system.
- Quasielastic light scattering microscope spectrometer.
- Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term ...
Schools
Johns Hopkins University School Of Medicine
Columbia Presby Med Center
Harvard Med Schjoint Center Rad Therapy
Doctors Specialties
- Radiation Oncology
Accepted Insurances
Awards
- Meaningful Use Stage 1 Certification
- Super Doctor
Education
-
Beth Israel Deaconess Medical Center -
New York Presbyterian Hospital - Columbia Campus -
Johns Hopkins University School of Medicine
Hospital
-
Brigham and Women's Hospital -
Massachusetts General Hospital -
Dana-Farber Cancer Institute
Drug Facts
| NPI NUMBER | 1013966464 | |
| NPPES Provider LastName | TISHLER | |
| NPPES Provider FirstName | ROY | |
| NPPES Provider ZIPCode | 02115 | |
| NPPES Provider State | MA | |
| Specialty Description | Radiation Oncology | |
| Total Claim Count | 11.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1013966464 |
| Last Name Of The Provider | TISHLER |
| First Name Of The Provider | ROY |
| View All |
Similar Doctors
|
|
Dr. Herman D. Suit, MD |
|
|
Dr. Ariel E. Marciscano, MD |
|
|
Dr. Kristina L. Mirabeau-Beale, MD |
|
|
Dr. Justin C. Voog, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Shyam K. Tanguturi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jennifer L. Pretz, MD |
|
|
Dr. Michael E. Pacold, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Tai C. Lam, MD |
|
|
Dr. Monica S. Krishnan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Elizabeth H. Baldini, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Brian M. Alexander, MD |
|
|
Dr. Abram Recht, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Helen A. Shih, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gregory A. Russo, MD |
|
|
Dr. Kathryn E. Huber, MD
This Doctor is OpenDoctor Recommended.
|